This post was originally published on this site It seems like years have passed since I published a column. In reality, it’s been less than two months. But as we know, life can change pretty drastically over the course of a week, let alone a couple of months. I know that mine certainly has, and…
Conditions
Conditions
Collaborators Aim to Identify OC Patients Likely to Benefit from New Combo Therapy
This post was originally published on this site The University of New Mexico (UNM) Comprehensive Cancer Center and the New Mexico Alliance for Cancer Care have entered a collaboration with Personalis to use its cancer immunogenomics platform to identify which ovarian cancer patients respond to a new combination therapy — Lynparza (olaparib) plus the investigational…
PSMA PET-CT Offers Better Detection Rates in Recurrent PC, Study Says
This post was originally published on this site The imaging agent 68Ga-PSMA-11 has better detection rates than 18F-fluciclovine in men with recurrent prostate cancer who have already had radical surgery to remove the prostate and whose levels of prostate-specific antigen (PSA, a marker of disease) are very low, a study says. The findings of the…
FTC Warns Companies Against Unsubstantiated Advertising of CBD Products for Fibromyalgia
This post was originally published on this site The U.S. Federal Trade Commission (FTC) sent warning letters to three companies that sell cannabis-based products containing cannabidiol (CBD), cautioning them that making unsubstantiated claims about the health benefits of CBD could lead to legal action. The agency “urges the companies to review all claims made for…
Keytruda and Inlyta Combo Approved in Europe for Untreated Advanced Kidney Cancer
This post was originally published on this site The European Commission has approved a combination of Keytruda (pembrolizumab) with Inlyta (axitinib) for the first-line treatment of patients with advanced renal cell carcinoma (RCC). The approval is based on the results of the multi-center KEYNOTE-426 Phase 3 trial (NCT02853331), which involved 861 untreated patients with metastatic…
2K’s WWE Video Game Will Help Raise Awareness of Blood Cancers
This post was originally published on this site In a campaign featuring World Wrestling Entertainment (WWE) superstar and leukemia survivor Roman Reigns, video game publisher 2K is partnering with the Leukemia & Lymphoma Society to heighten awareness around blood cancers. The global partnership corresponds with 2K’s release of professional wrestling video game WWE 2K20, slated…
Bryostatin-1 Fails to Ease Dementia in Moderate-to-Severe Alzheimer’s Patients in Phase 2 Trial
This post was originally published on this site An investigational Alzheimer’s treatment called bryostatin-1 failed to meet its primary goal — lesser evidence of dementia in people with more severe disease — in a Phase 2 clinical trial, Neurotrope, the company developing the therapy, announced in a press release. Bryostatin-1 is a molecule that activates…
Herceptin Developers Granted 2019 Lasker-DeBakey Research Award
This post was originally published on this site The 2019 Lasker-DeBakey Clinical Medical Research Award has been granted to scientists H. Michael Shepard, PhD, Dennis J. Slamon, MD, PhD, and Axel Ullrich, PhD, for their development of the breast cancer therapy Herceptin (trastuzumab). The Lasker Awards are widely regarded as America’s most prestigious biomedical research awards and…
First-line Imfinzi-Chemo Therapy Extends Survival of Patients with Aggressive Lung Cancer, Phase 3 Trial Shows
This post was originally published on this site Adding the immune checkpoint inhibitor Imfinzi (durvalumab) to standard chemotherapy care significantly extends the survival of patients with untreated extensive-stage small cell lung cancer (ES-SCLC), an aggressive form of lung cancer, a Phase 3 trial shows. The trial’s findings were presented at the Presidential Symposium of the…
Ygalo Continues to Show Promising Activity in Relapsed, Refractory Multiple Myeloma
This post was originally published on this site Ygalo (melflufen) combination therapy continues to demonstrate promising results, without significant side effects, in patients with relapsed or refractory multiple myeloma, updated data from two clinical trials show. The findings were presented at the Society of Hematologic Oncology (SOHO) 2019 Annual Meeting, held Sept. 11–14 in Houston,…
IMV, Wistar Institute Partner to Develop T-cell Immunotherapy Against Cancers with BRAF Mutations
This post was originally published on this site IMV announced that it has joined with the Wistar Institute to develop an immunotherapy targeting cancer cells with mutations in the BRAF gene. Such mutations are linked to some types of ovarian and other cancers. Under the partnership, IMV will use its proprietary DPX drug delivery platform to…
Study Describes New Imaging Technique for Detecting Prostate Cancer
This post was originally published on this site A new imaging technique that combines ultrasound and photoacoustic imaging of the prostate delivers detailed information about the prostate’s anatomy and cancer location, identifying some cancers that would be invisible to conventional imaging. The approach, called transrectal ultrasound and photoacoustic device, or TRUSPA, may enable earlier detection…